Corifollitropin alfa for poor responders patients, a prospective randomized study

BACKGROUND: Poor ovarian response remains one of the biggest challenges for reproductive endocrinologists. The introduction of corifollitropin alpha (CFA) offered an alternative option to other gonadotropins for its longer half-life, its more rapid achievement of the threshold and higher FSH levels....

Descripción completa

Detalles Bibliográficos
Autores principales: Fusi, F. M., Zanga, L., Arnoldi, M., Melis, S., Cappato, M., Candeloro, I., Di Pasqua, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346462/
https://www.ncbi.nlm.nih.gov/pubmed/32646462
http://dx.doi.org/10.1186/s12958-020-00628-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346462/
https://www.ncbi.nlm.nih.gov/pubmed/32646462
http://dx.doi.org/10.1186/s12958-020-00628-6

Ejemplares similares